Corcept Therapeutics
CORT
$117.17
+2.36%
Corcept Therapeutics Inc. is a commercial-stage pharmaceutical company focused on developing and marketing drugs that modulate the effects of cortisol to treat severe metabolic, oncologic, and neuropsychiatric disorders. Its lead product, Korlym (mifepristone), is approved for Cushing's syndrome, and the company is advancing a pipeline including relacorilant and dazucorilant for various cancers and other conditions. Corcept is a niche player in the selective cortisol modulation space, with a strong commercial franchise and a promising oncology pipeline. The current investor narrative centers on the recent FDA approval of Lifyorli, a new cancer drug, which has driven a massive stock rally and raised expectations for pipeline-driven growth, while also attracting scrutiny over insider selling and valuation sustainability.…
CORT
Corcept Therapeutics
$117.17
Related headlines
Investment Opinion: Should I buy CORT Today?
Based on the analysis, I rate CORT as a Buy. The thesis is that the FDA approval of Lifyorli provides a significant growth catalyst, and the company's strong balance sheet and high gross margins support long-term value creation. The analyst consensus is 'Buy' with an average target of $135.25, implying 18.2% upside. Supporting evidence includes the 199.7% YTD stock performance, the 98.3% gross margin, the debt-free balance sheet, and the forward PE of 25.3x, which is reasonable for a company with expected earnings growth of 44%.
Sign up to view all
CORT 12-Month Price Forecast
The AI model assesses a bullish stance with medium confidence. The FDA approval of Lifyorli is a tangible catalyst that could drive growth, and the company's high gross margins and strong balance sheet provide a solid foundation. However, the deceleration in revenue growth and negative operating income in Q1 2026 temper enthusiasm. The stance would be upgraded to high confidence if Lifyorli sales exceed expectations and revenue growth re-accelerates, while a downgrade would occur if pipeline setbacks or continued margin erosion emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Corcept Therapeutics's 12-month outlook, with a consensus price target around $135.25 and implied upside of +15.4% versus the current price.
Average Target
$135.25
0 analysts
Implied Upside
+15.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$50 - $165
Analyst target range
Corcept is covered by 4 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 2.25 (where 1 is Strong Buy and 5 is Sell). The average target price is $135.25, implying an upside of +18.2% from the current price of $114.47. The distribution includes 3 Buy ratings and 1 Hold/Peer Perform, reflecting a generally bullish sentiment, though the small number of analysts suggests limited coverage relative to its market cap.
Bulls vs Bears: CORT Investment Factors
Corcept presents a compelling bull case driven by the FDA approval of Lifyorli, which has the potential to transform the company's growth trajectory, supported by exceptional gross margins and a debt-free balance sheet. However, the bear case highlights decelerating revenue growth, negative operating income due to heavy R&D spending, and a rich valuation that leaves little room for error. Currently, the bull case has stronger evidence given the tangible catalyst of Lifyorli and the analyst consensus, but the key tension lies in whether the pipeline investment will translate into sustained revenue growth to justify the premium valuation. If Lifyorli commercial uptake disappoints or revenue growth continues to decelerate, the stock could face significant downside.
Bullish
- FDA approval of Lifyorli: The FDA approval of Lifyorli in March 2026 has opened a new revenue stream in oncology, driving a 199.7% YTD stock surge. This approval validates the company's pipeline and diversifies beyond Korlym, reducing reliance on a single product.
- Exceptional gross margins: Gross margin stands at 98.3% for Q1 2026, reflecting the low cost of goods for its pharmaceutical products. This high margin provides significant operating leverage and supports profitability as revenue scales.
- Strong balance sheet: Debt-to-equity is a mere 0.0094, indicating virtually no debt, while the current ratio of 2.92 shows ample liquidity. This financial strength provides a cushion for ongoing R&D investments and pipeline development.
- Analyst consensus Buy: With a consensus recommendation of 'Buy' and an average target price of $135.25, analysts see an 18.2% upside from the current price of $114.47. The high target of $165 suggests potential for further gains if pipeline milestones are met.
Bearish
- Decelerating revenue growth: Q1 2026 revenue grew only 4.9% YoY to $164.9M, a sharp slowdown from the 18.7% growth in Q2 2025. This deceleration raises concerns about the sustainability of the commercial franchise's growth momentum.
- Negative operating income: Operating margin swung to -30.1% in Q1 2026, driven by a surge in R&D and SGA expenses to $211.6M. This heavy investment in the pipeline has eroded profitability, with a net loss of -$31.2M in the quarter.
- Elevated valuation: Trailing PE is 36.6x, well above the sector average, and EV/EBITDA is 51.2x, indicating the market is pricing in substantial future growth. Any disappointment in pipeline or commercial execution could lead to multiple compression.
- Insider selling: Recent insider selling, though pre-scheduled, has raised concerns among investors. While the executive retains significant option holdings, the timing after the FDA approval and $1.05B outlook may signal a perceived peak in valuation.
CORT Technical Analysis
Corcept's stock has been in a powerful uptrend over the past year, with a 1-year price change of +58.99%, significantly outperforming the S&P 500's +20.37% over the same period. The current price of $114.47 sits near the top of its 52-week range, at approximately 93.7% of the high of $122.21 and well above the low of $28.66. This positioning near the highs indicates strong momentum and investor optimism, though it also raises concerns about overextension and potential for a pullback.
Beta
0.46
0.46x market volatility
Max Drawdown
-64.4%
Largest decline past year
52-Week Range
$29-$122
Price range past year
Annual Return
+63.3%
Cumulative gain past year
| Period | CORT Return | S&P 500 |
|---|---|---|
| 1m | +29.4% | +4.0% |
| 3m | +101.3% | +5.3% |
| 6m | +194.2% | +12.6% |
| 1y | +63.3% | +20.1% |
| ytd | +206.7% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CORT Fundamental Analysis
Revenue growth has been solid but decelerating, with the most recent quarter (Q1 2026) showing revenue of $164.9 million, up 4.89% year-over-year, compared to prior quarters that saw double-digit growth (e.g., Q2 2025 revenue of $194.4 million, up 18.7% YoY). The company's profitability has been inconsistent, with a net loss of -$31.2 million in Q1 2026, driven by a sharp increase in operating expenses, particularly R&D and SGA, which totaled $211.6 million. Gross margins remain exceptionally high at 98.3%, reflecting the low cost of goods for its pharmaceutical products, but operating margins have swung from positive in prior quarters (e.g., 13.7% in Q2 2025) to -30.1% in Q1 2026, indicating significant investment in pipeline development.
Quarterly Revenue
$164903000.0B
2026-03
Revenue YoY Growth
+4.9%
YoY Comparison
Gross Margin
98.3%
Latest Quarter
Free Cash Flow
$119788000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CORT Overvalued?
Given that Corcept's trailing twelve-month net income is positive (as of the latest data, EPS is $0.0276), I selected the PE ratio as the primary valuation metric. The trailing PE is 36.63x, while the forward PE is 25.34x, implying the market expects earnings growth of about 44% over the next year. This gap suggests that investors are pricing in a significant acceleration in profitability, likely driven by the recent FDA approval and pipeline progress.
PE
36.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 18x~56x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
51.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are notable: Q1 2026 saw a net loss of -$31.2 million and negative operating income of -$49.6 million, driven by a 38% YoY increase in operating expenses to $211.6 million. The company's reliance on continued revenue growth to fund its pipeline is evident, as free cash flow TTM is only $119.8 million, which may not cover the elevated spending. However, the balance sheet is strong with no debt and a current ratio of 2.92, providing a buffer. The deceleration in revenue growth to 4.9% YoY in Q1 2026 from double-digit rates in prior quarters is a concern, as it may indicate market saturation for Korlym or competitive pressures.
FAQ
The key risks include: 1) Financial risk from negative operating income and heavy R&D spending, which could pressure cash flow if revenue growth stalls. 2) Competitive risk from other cortisol modulators or oncology treatments that could limit Lifyorli's market share. 3) Regulatory risk from clinical trial failures or delays in pipeline candidates. 4) Valuation risk, as the stock trades at a premium multiple that could contract if growth disappoints. The most severe risk is a pipeline failure, which could send the stock down 50% or more.
The 12-month forecast is bullish, with a base case target of $135.25 (50% probability), a bull case of $165 (30% probability), and a bear case of $50 (20% probability). The base case assumes Lifyorli ramps gradually and Korlym remains stable. The bull case requires rapid Lifyorli uptake and positive pipeline data. The bear case would occur if Lifyorli fails or pipeline setbacks emerge. The most likely scenario is the base case, with the stock trading near the average analyst target.
CORT is trading at a trailing PE of 36.6x and a forward PE of 25.3x, which is a premium to the broader market but justified by expected earnings growth of 44%. The EV/EBITDA of 51.2x is high, indicating the market is pricing in significant future growth. Compared to its own history, the stock is near the high end of its valuation range, reflecting optimism about Lifyorli. The market expects the pipeline to deliver, and any disappointment could lead to multiple compression.
CORT is a good buy for investors with a high risk tolerance, given the 18.2% upside to the average analyst target of $135.25 and the potential for Lifyorli to drive growth. However, the stock is not without risks, including decelerating revenue growth and negative operating income. The recent FDA approval provides a strong catalyst, but the valuation at 36.6x trailing PE leaves little room for error. For those who believe in the pipeline, it could be a rewarding investment, but it is not suitable for conservative investors.
CORT is more suitable for long-term investment, given its pipeline-driven growth story and the potential for Lifyorli to expand the market. The stock has a beta of 0.455, indicating lower volatility than the market, but it has experienced significant swings, as seen in the 64.4% max drawdown. The company does not pay a dividend, so returns depend on capital appreciation. A minimum holding period of 3-5 years is recommended to allow pipeline catalysts to materialize and revenue to grow. Short-term trading is possible but risky due to the high valuation and sensitivity to news.